Colonic Diseases  >>  ganitumab (AMG 479)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ganitumab (AMG 479) / Takeda, ImmunityBio
QUILT-2.018, NCT00813605 / 2008-005301-19: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Completed
2
155
US, Europe, RoW
FOLFIRI, AMG 655, Conatumumab, Placebo, AMG 479
NantCell, Inc.
Metastatic Colorectal Cancer
01/11
06/12
NCT00891930 / 2008-004752-77: Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed
2
76
US, Europe
Panitumumab, Vectibix, Ganitumab, AMG 479, Irinotecan
Amgen
Metastatic Colorectal Cancer
07/13
07/13
NCT00819169 / 2008-005074-12: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Terminated
1b/2
89
US, Europe
AMG 479, AMG 655, AMG 655 is also known as conatumumab.
NantCell, Inc.
Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Solid Tumors
10/10
10/11
NCT00788957 / 2008-001751-21: Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark P1/2 data
Jun 2011 - Jun 2011: P1/2 data
Completed
1b/2
153
US, Canada, RoW
Panitumumab, Vectibix®, Ganitumab, AMG 479, Rilotumumab, AMG 102, Placebo
Amgen
Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer
02/12
10/13

Download Options